Chief Medical Officer
Andrea Pirzkall joined Replimune as Chief Medical Officer in 2020. Andrea brings extensive clinical, operational and regulatory experience having served in world class organizations in the biotech industry and academia. Most recently, Andrea served as Executive Director of Clinical Development at BeiGene, Ltd., a publicly traded commercial-stage biotechnology company. At BeiGene, she provided strategic oversight of, and worked closely with, global cross-functional teams on the development of tislelizumab (anti-PD1) and other pipeline agents, with a focus on thoracic indications, with positive outcomes of initial two pivotal studies in non-small cell lung cancer. She served also as the global clinical development lead on the BeiGene/Celgene joint development committee. Prior to BeiGene, Andrea was Principal Medical Director at Genentech, a member of the Roche Group. During her ten years at Genentech, she held roles of increasing responsibility and oversaw the design and execution of clinical development programs for numerous novel biologics including signaling pathway inhibitors, anti-angiogenics and immunotherapies in early to late stage development. Prior to industry, Andrea trained in radiation oncology and completed her dissertation at the University Heidelberg and the German Cancer Research Center (dkfz). Following a fellowship in Medical Physics/Radiation Oncology, she held joint appointments as Associate Adjunct Professor, in the departments of Radiation Oncology, Radiology, and Neurosurgery at the University of California, San Francisco (UCSF) where she helped pioneer the use of advanced imaging modalities to guide focal therapeutic interventions and assess response to standard of care and investigational targeted therapies. Andrea holds a Doctor of Medicine from Friedrich-Schiller University Jena, Germany.